

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Comparative trial of oral Ivermectin vs. Topical Lindane lotion 1% in the treatment of Scabies

Protocol summary

Summary

In this clinical trial study, 80 patients with Scabies, who were attended in the dermatology out patient department of Sina Hospital of Tabriz medical science, were examined, and efficacy of oral Ivermectin and topical Lindane lotion for treatment of Scabies, was compared. All patients were divided into two groups randomly. The key inclusion criteria: (nocturnal pruritus; burrow or/and typical scabietic lesion), and the key exclusion criteria: (under 2 years old; pregnancy; positive history of seizure or epilepsy; history of immunodeficiency diseases; history of anti scabies drug usage in last month.) The first group received single dose of 200 µg/kg body weight oral Ivermectin and the other group received topical Lindane lotion 1%. In the case of treatment failure at two week follow up, treatment was repeated. Treatment was evaluated at intervals of 2 and 4 weeks.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201205249844N1**

Registration date: **2014-07-13, 1393/04/22**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2014-07-13, 1393/04/22

Registrant information

Name

Mehdi Amirnia

Name of organization / entity

Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1540 6612

Email address

amirniyam@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Tabriz University of Medical Sciences

Expected recruitment start date

2012-04-03, 1391/01/15

Expected recruitment end date

2013-04-04, 1392/01/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative trial of oral Ivermectin vs. Topical Lindane lotion 1% in the treatment of Scabies

Public title

Efficacy of oral Ivermectin for treatment of Scabies

Purpose

Treatment

Inclusion/Exclusion criteria

Exclusion criteria: (Under 2 years old; Pregnancy ; Positive history of seizure or epilepsy ; Positive history of immunodeficiency diseases; History of anti scabies drug usage in last month .) Inclusion criteria: (Nocturnal pruritus; Burrow or/and typical scabietic lesion on the classical sites; History of similar symptoms in their families .)

Age

From **2 years** old to **100 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: 80

Randomization (investigator's opinion)

N/A

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethic committee of Tabriz University of Medical Sciences.

Street address

Gol Central Building of Tabriz University of Medical Sciences, Ghasht Ave, Tabriz

City

Tabriz

Postal code**Approval date**

2014-06-16, 1393/03/26

Ethics committee reference number

9296

Health conditions studied**1****Description of health condition studied**

Scabies

ICD-10 code

XII

ICD-10 code description

Scabies, sarcoptic itch

Primary outcomes**1****Description**

Response to the treatment of the old lesion and absence of new lesion

Timepoint

2, 4 weeks after treatment

Method of measurement

Physical examination and comparing old lesion picture with the site of lesion after medical treatment

Secondary outcomes**1****Description**

Absence of pruritus of lesion

Timepoint

2, 4 weeks after the treatment

Method of measurement

physical examination

Intervention groups**1****Description**

Group A received single dose of 200 mic/kg oral ivermectin, repeat other dose at second week after treatment.

Category

Treatment - Drugs

2**Description**

Group B received 30 ml, topical lindane lotion 1% , on all body surface at night and removed 8 to 12 hours later. Repeat other dose at second week after treatment.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Dermatology Department of Sina Hospital, Tabriz University of Medical Sciences.

Full name of responsible person

Elnaz Poorhasani

Street address

Sina Hospital, Azadi Ave.

City

Tabriz

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Vice chancellor for research, Tabriz University of Medical Sciences, Daneshgah Square.

Full name of responsible person

Dr Mehdi Amirnia

Street address

Vice chancellor for research, Tabriz University of Medical Sciences, Central Building of Medical Sciences, Daneshgah Square.

City

Tabriz

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice chancellor for research, Tabriz University of Medical Sciences, Daneshgah Square.

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Daneshgah Square, Tabriz University of Medical Sciences

Full name of responsible person

Elnaz Poorhasani

Position

MD

Other areas of specialty/work**Street address**

Dermatology Department, Sina Hospital, Azadi Ave.

City

Tabriz

Postal code**Phone**

+98 41 1541 2101

Fax**Email**

el.poorhasani@gmail

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Dermatology Department, Sina Hospital, Tabriz University of Medical Sciences.

Full name of responsible person

Dr Mehdi Amirnia

Position

Dermatologist

Other areas of specialty/work**Street address**

Sina Hospital, Azadi Ave.

City

Tabriz

Postal code**Phone**

+98 41 1541 2101

Fax**Email**

el.poorhasani@gmail

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Dermatology Department, Sina Hospital, Tabriz University of Medical Sciences

Full name of responsible person

Elnaz Poorhasani

Position

MD

Other areas of specialty/work**Street address**

Dermatology Department, Sina Hospital, Azadi Ave.

City

Tabriz

Postal code**Phone**

+98 41 1541 2101

Fax**Email**

el.poorhasani@gmail

Web page address**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty